KR20070008763A - A functional food containing composition for the improvement of diabetes mellitus - Google Patents
A functional food containing composition for the improvement of diabetes mellitus Download PDFInfo
- Publication number
- KR20070008763A KR20070008763A KR1020050062513A KR20050062513A KR20070008763A KR 20070008763 A KR20070008763 A KR 20070008763A KR 1020050062513 A KR1020050062513 A KR 1020050062513A KR 20050062513 A KR20050062513 A KR 20050062513A KR 20070008763 A KR20070008763 A KR 20070008763A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- powder
- functional food
- health functional
- cinnamon
- Prior art date
Links
- 235000013376 functional food Nutrition 0.000 title claims abstract description 28
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 27
- 230000006872 improvement Effects 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 title description 18
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 53
- 241000219051 Fagopyrum Species 0.000 claims abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 208000024891 symptom Diseases 0.000 claims abstract description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 4
- 239000000654 additive Substances 0.000 claims abstract 3
- 230000000996 additive effect Effects 0.000 claims abstract 3
- 239000000796 flavoring agent Substances 0.000 claims abstract 3
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims description 61
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 37
- 239000000843 powder Substances 0.000 claims description 36
- 235000007164 Oryza sativa Nutrition 0.000 claims description 35
- 235000009566 rice Nutrition 0.000 claims description 35
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 32
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 28
- 235000017803 cinnamon Nutrition 0.000 claims description 28
- 240000006891 Artemisia vulgaris Species 0.000 claims description 26
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 19
- 101710088194 Dehydrogenase Proteins 0.000 claims description 17
- 102000030595 Glucokinase Human genes 0.000 claims description 17
- 108010021582 Glucokinase Proteins 0.000 claims description 17
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 15
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 13
- 239000011574 phosphorus Substances 0.000 claims description 13
- 229910052698 phosphorus Inorganic materials 0.000 claims description 13
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 10
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 6
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 6
- 240000001851 Artemisia dracunculus Species 0.000 claims description 6
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 6
- 239000001138 artemisia absinthium Substances 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- 235000020230 cinnamon extract Nutrition 0.000 claims description 5
- 229960003495 thiamine Drugs 0.000 claims description 5
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 235000019157 thiamine Nutrition 0.000 claims description 4
- 239000011721 thiamine Substances 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 241000209094 Oryza Species 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 21
- 102000004190 Enzymes Human genes 0.000 abstract description 17
- 108090000790 Enzymes Proteins 0.000 abstract description 17
- 238000002156 mixing Methods 0.000 abstract description 12
- 239000002075 main ingredient Substances 0.000 abstract description 9
- 241001264174 Cordyceps militaris Species 0.000 abstract description 6
- 230000004153 glucose metabolism Effects 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 6
- 239000012153 distilled water Substances 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 235000001497 healthy food Nutrition 0.000 abstract 3
- 235000008658 Artemisia capillaris Nutrition 0.000 abstract 2
- 241000092668 Artemisia capillaris Species 0.000 abstract 2
- 239000008989 cinnamomi cortex Substances 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 235000000346 sugar Nutrition 0.000 description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 235000012054 meals Nutrition 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000011777 magnesium Substances 0.000 description 10
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 241000190633 Cordyceps Species 0.000 description 6
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 230000000291 postprandial effect Effects 0.000 description 6
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000237536 Mytilus edulis Species 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000006049 herbal material Substances 0.000 description 4
- 235000020638 mussel Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HVTQDSGGHBWVTR-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-phenylmethoxypyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound C(C1=CC=CC=C1)OC1=NN(C=C1C=1C=NC(=NC=1)NC1CC2=CC=CC=C2C1)CC(=O)N1CCOCC1 HVTQDSGGHBWVTR-UHFFFAOYSA-N 0.000 description 3
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 3
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 3
- 108010018763 Biotin carboxylase Proteins 0.000 description 3
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000245665 Taraxacum Species 0.000 description 3
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000002196 fr. b Anatomy 0.000 description 3
- 210000003918 fraction a Anatomy 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 240000002045 Guettarda speciosa Species 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 235000019206 astragalus extract Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 sucrose fatty acid ester Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241001464798 Anguis Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000016887 Leptospermum scoparium Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940067866 dandelion extract Drugs 0.000 description 1
- 235000020691 dandelion extract Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- UJJGFDMKDZRNFG-UHFFFAOYSA-N n-nitro-n-phenylacetamide Chemical compound CC(=O)N([N+]([O-])=O)C1=CC=CC=C1 UJJGFDMKDZRNFG-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000001845 taraxacum officinale leaf extract Substances 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940119569 wormwood extract Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Pediatric Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
도 1은 다양한 생약소재들에 의한 글루코키나아제의 활성치를 나타낸 그래프이다.1 is a graph showing the activity of glucokinase by various herbal materials.
도 2은 다양한 생약소재들에 의한 피루베이트 디하이드로게나아제의 활성치를 나타낸 그래프이다.Figure 2 is a graph showing the activity of pyruvate dehydrogenase by various herbal materials.
도 3은 다양한 생약소재들에 의한 아세틸-코에이 카르복실라제의 활성치를 나타낸 그래프이다.Figure 3 is a graph showing the activity of acetyl-Coei carboxylase by various herbal materials.
도 4는 글루코키나아제의 활성을 도시한 도표이다.4 is a diagram depicting the activity of glucokinase.
도 5는 피루베이트 디하이드로게나아제의 활성을 도시한 도표이다.5 is a diagram depicting the activity of pyruvate dehydrogenase.
도 6은 아세틸-코에이 카르복실라제의 활성을 도시한 도표이다. 6 is a chart depicting the activity of acetyl-Coei carboxylase.
본 발명은 당뇨병 환자를 위한 건강기능식품에 관한 것으로, 보다 상세하게는 동충하초, 메밀쌀, 인진쑥 및 계피를 주성분으로 함유하는 건강기능식품에 관한 것이다.The present invention relates to a health functional food for diabetics, and more particularly, to a health functional food containing Cordyceps sinensis, buckwheat rice, phosphorus mugwort and cinnamon as main ingredients.
당뇨병은 혈중 포도당 농도의 상승, 인슐린 부족 또는 인슐린 작용의 감소, 포도당, 지방과 단백질 대사의 이상과 이로 인한 급·만성 합병증의 발생으로 특징지어지는 질환이다. 당뇨병은 보통 기존의 인슐린이나 경구 혈당 강하제의 투여로 치료가 이루어지고 있는데, 이로써 근원적으로 치료하는데 한계가 있고, 경제적 부담과 더불어 부작용의 위험도 수반하고 있어, 근래에 와서는 식이요법 및 자연요법에 근거하여 대부분의 환자들이 쉽게 접근할 수 있는 여러 종류의 민간요법이 시도되고 있는 실정으로 천연식물 등의 약리물질을 탐색하는 연구가 이루어지고 있다. 그러나 상당수는 과학적 근거가 희박하고 치료효과나 부작용에 대한 이론이 정립되지 않아 심각한 문제를 유발할 수 있다. 그러므로 항당뇨 관련 기전상의 과학적 근거를 가지고 부작용 없이 당뇨병을 개선하거나 치유할 수 있는 물질을 발굴, 검증 그리고 활용하여 건강기능식품을 개발한다면 문제가 개선될 수 있을 것이다.Diabetes is a disease characterized by elevated blood glucose levels, insulin deficiency or decreased insulin action, abnormalities in glucose, fat and protein metabolism, and the resulting acute and chronic complications. Diabetes is usually treated with the administration of conventional insulin or oral hypoglycemic agents, which are fundamentally limited in treatment, and involve economic risks and risks of side effects. As a result, various types of folk remedies that are easily accessible to most patients have been attempted, and researches on pharmacological substances such as natural plants have been conducted. Many, however, have little scientific evidence and theories about therapeutic effects or side effects can be serious, causing serious problems. Therefore, the problem can be improved by developing health functional foods by discovering, validating and utilizing substances that can improve or cure diabetes without side effects with the scientific basis of anti-diabetic mechanism.
대한민국 특허공개 제 2002-0087570 호에는 누에 기주의 동충하초가 당뇨병 치료 효과를 갖는다고 제시되어 있는 바, 이에 본 발명자들은 당뇨병 치료 효과로 이미 공지된 동충하초를 그대로 포함시키면서 보다 효과적으로 혈당을 낮출 수 있는 또 다른 천연 소재들을 발견해 내고자 발명하고자 거듭 노력하였다. 특히 동충하초는 당뇨병 치료 뿐만 아니라, 항암작용이나 항균작용 등의 여러 가지 약리기전을 가지고 있으므로 한약 재료로서도 상당히 고가에 판매되고 있는 실정이다. 이 러한 동충하초만을 주성분으로 하는 건강기능식품은 당뇨병 치료 효과를 만족시키기에는 재료비의 부담이 상당하다 할 것이다. 그러므로, 동충하초 뿐만 아니라 그 외에 혈당강하 작용이 있는 다른 생약 소재들을 선별하여 그러한 소재들을 주성분으로 함유하는 건강기능식품을 개발하는 것은 시급한 문제라 할 수 있다. Korean Patent Laid-Open Publication No. 2002-0087570 suggests that the silkworm herbaceous cordyceps has a therapeutic effect on diabetes. Therefore, the present inventors have yet another method for lowering blood sugar while including cordyceps already known as a diabetes treatment effect. We tried to invent to find natural materials. In particular, Cordyceps sinensis has various pharmacological mechanisms such as anti-cancer activity and antimicrobial action, as well as diabetes treatment, and is being sold at a very high price as a herbal medicine material. Health functional foods containing only Cordyceps sinensis as the main ingredient will have a considerable burden on material costs to satisfy the effects of diabetes treatment. Therefore, it is urgent to develop not only cordyceps but also other herbal medicines with hypoglycemic action to develop health functional foods containing such ingredients as main ingredients.
이에 본 발명자들은 체내로 흡수된 포도당을 각 조직의 세포가 이용하는 속도를 증가시켜 혈중에 포도당이 과도하게 머무는 시간을 감소시키도록 하기 위하여 포도당 대사에 관여하는 효소들의 활성을 증가시키는 생약 소재들을 선별하기에 이르렀으며, 이들의 적절한 혼합비를 통하여 포도당 대사 관련 효소의 활성이 증가됨을 확인하고 이로써 당뇨병 증상을 개선시킬 수 있는 기능성식품을 개발함으로써 본 발명을 완성하였다.Accordingly, the present inventors screened herbal medicines that increase the activity of enzymes involved in glucose metabolism in order to increase the rate at which cells of each tissue utilize glucose absorbed into the body, thereby reducing the excessive time of glucose staying in the blood. The present invention was completed by confirming that the activity of glucose-related enzymes is increased through a proper mixing ratio thereof, thereby developing a functional food that can improve diabetes symptoms.
본 발명은 세포내 포도당 대사에 관련한 효소들을 활성시키는 작용이 있는 천연생약 소재들의 추출물을 주성분으로 함유하는 당뇨병 환자를 위한 혈당강하용 기능성식품을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a hypoglycemic functional food for diabetic patients containing extracts of natural herbal materials having the function of activating enzymes related to intracellular glucose metabolism as a main component.
또한 본 발명은 혈당강하제 투여 등의 약물치료가 근원적인 당뇨병 치료로써는 부족한 문제점 및 부작용 등을 극복할 수 있을 것으로 기대되는 혈당강하기능의 식품을 제공하는 것을 목적으로 한다.In addition, an object of the present invention is to provide a food for hypoglycemic activity that is expected to be able to overcome the problems and side effects that the drug treatment, such as the administration of hypoglycemic agents is insufficient as a fundamental diabetes treatment.
상기의 목적을 달성하기 위해 본 발명은 동충하초 추출물에 세포내 포도당 대사에 관련된 효소들을 활성화시키는 작용이 있는 메밀쌀 추출물이나 인진쑥 추출물 또는 계피 추출물을 주성분으로 포함함을 특징으로 하는 당뇨병 환자를 위한 건강기능식품을 제공한다.In order to achieve the above object, the present invention is a health function for diabetic patients, comprising buckwheat rice extract or jinjin mugwort extract or cinnamon extract as a main component in the Cordyceps sinensis extract, which activates enzymes related to intracellular glucose metabolism. Provide food.
어떤 형태의 당뇨이던지 증상의 개선이나 치유의 기본 원리는 식사 후 체내로 흡수된 당을 각 조직의 세포가 이용하는 속도를 증가시켜 혈중에 당이 과도하게 머무는 시간을 감소시키는 것이다. 이를 위하여 세포 내로 흡수된 당의 이용 속도를 증가시키려면 세포내 당대사 기전에 있어서 첫번째 단계인 글루코스가 피루베이트(Pyruvate)로 분해되도록 하는 과정에서 작용하는 글루코키나아제의 활성을 증가시키도록 하여야 한다. 그러나 이 과정은 가역적인 반응이기 때문에 글루코키나아제의 활성만 증가시킬 수 있는 소재는 당의 이용 속도를 계속적으로 증가시킬 수 없으므로, 다음 단계인 비가역적 반응에 작용하는 활성형의 피루베이트 디하이드로게나아제(Pyruvate dehydrogenase)의 활성을 증가시킬 수 있어야 한다. 또한 이때 생산되는 다량의 APT를 운동 등을 통해 소비해줘야 되는데 그렇지 못하다면 이 반응의 속도 증가는 제한 받게 되는 결과를 낳으므로 피루베이트 디하이드로게나아제의 다음 단계인 아세틸-코에이(Acetyl-CoA)를 지방으로 전환하여 저장하는 속도를 증가시키도록하는 과정에서 관여하는 효소인 아세틸-코에이 카르복실라제(Acetyl-CoA caroxylase)의 활성이 증가되면 효율적으로 혈당의 감소를 유도할 수 있게 된다.Whatever the type of diabetes, the basic principle of symptom improvement or healing is to increase the rate at which cells in each tissue take up the sugar absorbed into the body after a meal, thereby reducing the time the sugar stays in the blood. For this purpose, to increase the utilization rate of sugar absorbed into cells, it is necessary to increase the activity of glucokinase which acts in the process of decomposing glucose into pyruvate, the first step in intracellular glucose metabolism. However, since this process is a reversible reaction, a material that can only increase the activity of glucokinase cannot continuously increase the rate of sugar utilization, so the active pyruvate dehydrogenase that acts on the next step, irreversible reaction ( It should be possible to increase the activity of pyruvate dehydrogenase. In addition, a large amount of APT produced must be consumed through exercise or the like. Otherwise, the increase of the reaction rate will be limited, so the next step of pyruvate dehydrogenase, acetyl-CoA Increasing the activity of the enzyme acetyl-CoA carboxylase (Acetyl-CoA caroxylase) involved in the process to increase the rate of storage to fat to be able to efficiently reduce blood sugar.
이에 따라 본 발명자들은 당뇨병 환자를 위한 건강기능식품의 주성분으로서 사용될 소재를 탐색하기 위하여 새포내 당대사에 관련된 효소들인 글루코키나아제, 피루베이트 디하이드로게나아제 또는 아세틸-코에이 카르복실라제의 활성을 증가시킬수 있는 소재를 지속적으로 탐색하였으며 그 소재들의 조합도 함께 탐색하였다. 결국 새로운 기능성식품의 소재로서 천연물 소재인 동충하초, 메밀쌀, 인진쑥 및 계피를 선별하였다.Accordingly, the present inventors have increased the activity of glucokinase, pyruvate dehydrogenase, or acetyl-coei carboxylase, enzymes related to sugar metabolism in macrophages, in order to search for materials to be used as main components of dietary supplements for diabetics. We continuously searched for materials that could be made and the combination of materials. In the end, we selected the natural ingredients such as Cordyceps, buckwheat rice, Injin mugwort and Cinnamon as new functional foods.
동충하초(冬蟲夏草)는 곰팡이의 일종인 동충하초균이 주로 온도, 습도가 높아지는 시기에 살아있는 곤충의 몸 속으로 들어가 발육증식하면서 기주곤충을 죽이고 얼마 후 자실체를 곤충의 표피에 형성하는 일종의 약용버섯으로 항균작용이 강하고 중추신경계작용, 호흡계통작용, 심장혈관작용, 항암작용, 면역증강작용, 항피로작용, 항노화작용 등의 약리기전이 있는 것으로 알려져 있다.Cordyceps sinensis (冬蟲夏草) is a kind of medicinal mushroom that forms a fruiting body on the epidermis of insects after some time when the fungus Cordyceps fungus enters the body of living insects at the time of high temperature and humidity. It is known to have strong pharmacological mechanisms such as central nervous system action, respiratory system action, cardiovascular action, anticancer action, immune enhancing action, anti-fatigue action and anti-aging action.
메밀쌀은 마디풀과의 일년초로서 중앙아시아에서 들어온 재배 식물로서 대장 같은 소화기 기능을 튼튼하게 하고 기력을 회복에 도움이 되어 소화가 안될 때, 이질, 여성대하, 동맥경화, 고혈압 같은 병에 많이 쓰이는 것으로 알려져 있다.Buckwheat rice is a cultivated plant from Central Asia that has been found in Central Asia. It is used for diseases such as dysentery, female treat, arteriosclerosis, and high blood pressure when it is indigestible because it strengthens digestive function like colon and helps to restore energy. Known.
인진쑥은 잎은 쑥처럼 생겼으나 쑥잎보다 약간 가늘면서도 대는 쑥보다 더 크게 자라는 약초로 간에 열이 있어 나타나는 증상인 간염, 황달 등에 쓰는 것으로 알려져 있다.Injin mugwort is a herb that looks like wormwood but grows slightly thinner than wormwood but is bigger than wormwood and is known to be used for hepatitis, jaundice, etc.
계피는 계수나무의 뿌리 ·줄기 ·가지 등의 껍질을 벗겨서 말리거나, 껍질을 벗기지 않고 건조시킨 가느다란 가지를 말하며 위장운동을 좋게하고 혈액순환 촉진이나 혈압강하 등에 유용한 것으로 알려져 있다.Cinnamon refers to thin branches dried and peeled without peeling the roots, stems, and branches of cassia. It is known to be useful for promoting gastrointestinal movement, promoting blood circulation and lowering blood pressure.
본 발명은 동충하초, 메밀쌀, 메밀피, 메밀싹, 인진쑥, 계피, 민들레, 차가버섯, 당귀, 피부백삼, 오가목, 황기추출물 및 녹색입홍합의 여러 생약재들이 포도당 관련 효소들의 활성에 미치는 영향을 측정하였다. 상기 각 생약재들을 재료로 하여 실험예 1 내지 4 에서와 같이 추출물을 분리해 내었으며 그리하여, 동충하초 추출물, 메밀쌀 추출물, 메밀피 추출물, 메밀싹 추출물, 인진쑥 추출물, 계피 추출물, 민들레 추출물, 차가버섯 추출물, 당귀 추출물, 피부백삼 추출물, 오가목 추출물, 황기추출물 및 녹색입홍합 추출물을 각각 실험예 5 내지 7에 기재된 바와 같이 실험하여 당분해 관련 효소인 글루코키나아제, 피루베이트 디하이드로게나아제, 아세틸-코에이 카르복시라아제의 활성에 미치는 활성값을 측정하였다. 특히, 메밀피와 메밀쌀의 경우는 그 비율을 1:3, 2:2, 3:1 로 다르게 하여 혼합한 것으로부터의 추출물을 분리하여 실험예 5 내지 7에 기재된 방법으로 실험하였다. 또한 동충하초의 경우에는 실험예 4와 같이 분획물 A 와 B 의 각각을 측정했을 뿐만 아니라 A와 B의 비율을 1:3, 2:2, 3:1로 하여 측정하였다. The present invention is to examine the effect of various herbal medicines of Cordyceps sinensis, buckwheat rice, buckwheat buckwheat, buckwheat sprout, jinjin mugwort, cinnamon, dandelion, chaga, angui, skin white ginseng, cucumber, astragalus extract and green lipped mussel on the activity of glucose related enzymes. Measured. The extracts were isolated as in Experimental Examples 1 to 4 using the respective herbal medicines, and thus, Cordyceps sinensis extract, buckwheat rice extract, buckwheat extract, buckwheat sprout extract, jinjin worm extract, cinnamon extract, dandelion extract, chaga extract , Angelica extract, skin white ginseng extract, Acacia extract, Astragalus extract and green lipped mussel extract, respectively, were tested as described in Experimental Examples 5 to 7 for glycolysis related enzymes glucokinase, pyruvate dehydrogenase, and acetyl-co The activity value on the activity of A carboxylase was measured. In particular, in the case of buckwheat and buckwheat rice, the extract from the mixture of different ratios of 1: 3, 2: 2, 3: 1 was separated and tested by the methods described in Experimental Examples 5-7. In addition, in the case of Cordyceps sinensis, each of the fractions A and B was measured as in Experiment 4, and the ratio of A and B was determined to be 1: 3, 2: 2, and 3: 1.
이 실험에 있어서 상기 세가지 효소들의 활성값은 상기 재료군에 대한 대조 군을 선정하여 그에 대한 백분율로 나타내었다. 대조군은 쌀과 옥수수를 혼합한 것으로부터 얻은 추출물로써 어떤 보조인자도 첨가하지 않은 것을 100%의 활성치로 보고 그에 대한 백분율로 계산하였으며 그 결과는 도 1, 2, 3 과 같다.In this experiment, the activity values of the three enzymes were expressed as a percentage of a control group for the material group. The control group was an extract obtained from a mixture of rice and corn, which was not added with any cofactor as an activity value of 100%, calculated as a percentage thereof, and the results are shown in FIGS. 1, 2 and 3.
도 1, 2, 3 에 따르면 동충하초 추출물은 측정한 항당뇨 관련 효소 3종 모두에서 높은 활성 증가를 나타내었으며 도 1의 글루코키나아제의 경우에는 타 샘플들 보다 탁월하게 높은 활성을 나타내었다. 또한 분획물 A와 분획물 B를 3 : 1 의 비율로 한 경우 각각의 효소에 있어서 최고의 활성을 보였다.According to Figures 1, 2, 3 Cordyceps sinensis extract showed a high activity increase in all three anti-diabetic enzymes measured, and in the case of the glucokinase of Figure 1 showed a significantly higher activity than other samples. In addition, fraction A and fraction B in the ratio of 3: 1 showed the highest activity for each enzyme.
메밀류들의 추출물에 관하여서는 메밀싹이 글루코키나아제(도 1)와 아세틸-코에이 카르복시라제(도 3) 활성에 가장 영향을 끼쳤지만 피루베이트 디하이드로게나아제(도 2)의 경우에는 메밀쌀이 그 활성을 가장 높게 하였으며 탁월하였다.In terms of extracts of buckwheat, buckwheat sprout had the most effect on glucokinase (FIG. 1) and acetyl-CoA carboxylase (FIG. 3) activities, but buckwheat rice for pyruvate dehydrogenase (FIG. 2). This activity was the highest and was excellent.
인진쑥도 효소들의 활성을 높히는 역할을 하였으며 특히 아세틸-코에이 카르복시라제(도 3)의 활성을 높히는데 상당한 영향을 끼쳤다. Phosphorus cucurbita also played a role in enhancing the activity of enzymes, and in particular, significantly affected the activity of acetyl-Coei carboxylase (FIG. 3).
또한, 계피의 경우는 세 가지 효소 모두(도 1, 2, 3)에서 두번째로 높은 활성을 나타내는 것으로 혈당강하에 좋은 역할을 하는 소재임이 파악되었다.In addition, the case of cinnamon was the second highest activity in all three enzymes (Fig. 1, 2, 3) was found to be a material that plays a good role in lowering blood sugar.
그리고, 상기의 실험에서 Cr3+, Mg2+ 및 TPP 등 세가지 보조인자를 다 첨가한 경우가 Mg2+,TPP 만을 첨가한 경우나 세가지 보조인자를 다 첨가하지 않은 경우보다 월등한 증가를 나타내는 것이 확인되었다. In the above experiments, the addition of all three cofactors, such as Cr 3+ , Mg 2+ and TPP, showed a much greater increase than the addition of Mg 2+ , TTP alone or the absence of all three cofactors. It was confirmed.
상기 실험을 통하여 당관련의 세가지 효소의 활성을 증가시키는데 적당한 소재로서 동충하초(Cordyceps militaris) 이외에도 메밀류, 인진쑥 및 계피가 선택되었다. Through this experiment, buckwheat, jinjin mugwort and cinnamon were selected in addition to Cordyceps militaris as a suitable material for increasing the activity of three enzymes related to sugar.
동충하초가 글루코키나아제의 활성을 탁월히 증가시켜주지만 이 과정은 가역적 반응이므로 당의 이용 속도를 계속적으로 증가시킬 수 없으므로, 가역적 반응에 작용하는 피루베이트 디하이드로게나아제의 활성을 증가시키는 메밀쌀 성분을 더 첨가시키는 것이 바람직하다.Cordyceps sinensis significantly increases the activity of glucokinase, but since this process is a reversible reaction, it is not possible to continuously increase the rate of utilization of sugars, so more buckwheat rice components that increase the activity of pyruvate dehydrogenase acting on the reversible reaction It is preferable to add.
그리고, 동충하초가 글루코키나아제의 활성을 탁월히 증가시켜주지만 결국 TCA회로를 통해 생산되는 다량의 ATP를 소비해줘야만 반응 속도 증가가 제한받게 되지 않으므로 아세틸-코에이를 지방으로 전환하는 속도를 증가시키는 아세틸-코에이 카르복시라제의 활성을 증가시키는 인진쑥 성분을 더 첨가시키는 것이 바람직하다.In addition, Cordyceps sinensis significantly increases the activity of glucokinase, but acetyl-Coay increases the rate of conversion of acetyl-CoA to fat since the reaction rate is not limited only by consuming a large amount of ATP produced through the TCA cycle. It is desirable to further add a ginko worm component that increases the activity of koei carboxylase.
또한, 당대사 관련 효소들의 활성을 높여 주는데 탁월한 기능을 하는 동충하초, 메밀쌀, 인진쑥 및 계피의 성분을 다 포함하도록 하는 것이 바람직하다. In addition, it is desirable to include all the components of Cordyceps sinensis, buckwheat rice, phosphorus mugwort and cinnamon which have an excellent function in enhancing the activity of sugar metabolism-related enzymes.
선택된 4가지 소재를 여러가지 중량비로 혼합한 경우에 실험예 1 내지 3의 방법으로 각 효소별 활성을 측정한 값은 다음과 같다.In the case where four selected materials were mixed in various weight ratios, the activity of each enzyme was measured by the method of Experimental Examples 1 to 3 as follows.
[표1] 선택소재와 배합별 글루코키나아제의 활성치 측정결과[Table 1] Results of activity measurements of glucokinase by selected materials and formulations
(대조군의 분당 NADPH의 생성량을 100%로 보고 그에 대한 백분율로 표시)(Reports 100% NADPH production per minute in the control group and displays it as a percentage)
[표2] 선택소재와 배합별 피루베이트 디하이드로게나제 활성치 측정결과[Table 2] Pyruvate dehydrogenase activity measurement results by selected material and formulation
(대조군의 분당 ρ-Nitroaniline의 반응량을 100%로 보고 그에 대한 백분율로 표시)(Review the response of ρ-Nitroaniline per minute of the control as 100% and express it as a percentage)
[표3] 선택소재와 배합별 아세틸-코에이 카르복시라제 활성치 측정결과[Table 3] Measurement results of acetyl-CoA carboxylase activity by selected material and formulation
(대조군의 분당 NADP의 반응량을 100%로 보고 그에대한 백분율로 표시)(Review the response of NADP per minute of the control as 100% and express it as a percentage)
상기 [표1]에 따르면 글루코키나아제의 활성은 4가지 선택 재료 중에서 동충하초만으로 이루어진 실시예 1의 경우가 가장 높았으나 실시예 6, 실시예 7, 실시예 8, 실시예 9, 실시예 10의 경우에 있어서는 동충하초만 선택하였을 때인 실시예 1의 효과와 비슷하거나 보다 더 높게 나타났다. 그 뿐만 아니라 동충하초는 가격의 면에서 다른 생약소재 등과 비교하여 비싼 소재로써 대량구입이 쉽지 않으므로 다른 생약 소재를 함유하지 않고 동충하초 추출물만 주성분으로 하는 경우에는 비경제적이라고도 할 수 있다. 그러므로 메밀쌀, 인진쑥 및 계피를 적절한 중량비로 배합함으로써 동충하초만의 혈당강하 효능보다 좀 더 높은 효능을 지니면서도 경제성을 고려한 중량비의 배합을 확인할 수 있게 되었다. According to Table 1, the activity of glucokinase was the highest in Example 1 consisting of Cordyceps sinensis among the four selected materials, but in Example 6, Example 7, Example 8, Example 9, and Example 10 In the case of Cordyceps sinensis only selected or similar to or higher than the effect of Example 1 appeared. In addition, Cordyceps sinensis is an expensive material compared to other herbal medicines in terms of price, so it is not easy to buy a large quantity, so it can be said that it is uneconomical when only Cordyceps sinensis extract is the main ingredient without other herbal medicines. Therefore, by combining buckwheat rice, ginjin mugwort and cinnamon in an appropriate weight ratio, it is possible to confirm the formulation of weight ratio in consideration of economic efficiency while having higher efficacy than the blood sugar lowering effect of Cordyceps sinensis.
상기 [표2] 및 [표3]에 따르면 4가지 선택 재료 중에서 피루베이트 디하이 드로게나아제의 활성은 메밀쌀만 선택한 실시예 2의 경우에 가장 높고, 아세틸-코에이하이드록시라제의 활성은 인진쑥만 선택한 실시예 3의 경우에 가장 높지만 실시예 6, 실시예 7, 실시예 8, 실시예 9, 실시예 10 의 경우에 각 효소의 활성이 훨씬 더 높게 측정되었다.According to Tables 2 and 3, the activity of pyruvate dehydrogenase among the four selected materials was the highest in Example 2 where only buckwheat rice was selected, and the activity of acetyl-coeihydroxylase was The highest activity was obtained for Example 3, which was selected only from Injin mugwort, but the activity of each enzyme was determined to be much higher for Examples 6, 7, 7, 8, 9, and 10.
즉 동충하초 추출물, 메밀쌀 추출물, 인진쑥 추출물 및 계피 추출물을 4 ∼ 8 : 0.5 ∼ 1.7 : 0.8 ∼ 2.1 : 1 ∼ 2.2 범위의 중량비 이외의 비율에 있어서는 피루베이트 디하이드로게나제와 아세틸코에이-하이드로시라제의 활성이 떨어진다.In other words, Cordyceps sinensis extract, Buckwheat rice extract, Insam wormwood extract and Cinnamon extract in the ratio other than the weight ratio in the range of 4-8: 0.5-1.7: 0.8-2.1: 1-2.2 The activity of the agent is reduced.
본 발명에 따른 각 성분의 중량비는 그들의 종류에 따라서 다양하게 설정될 수 있지만, 예를 들면 다음과 같은 중량비가 바람직하다.Although the weight ratio of each component which concerns on this invention can be set variously according to their kind, For example, the following weight ratio is preferable.
본 발명의 혼합조성물 중 동충하초 추출물, 메밀쌀 추출물, 인진쑥 추출물 및 계피 추출물을 4 ∼ 8 : 0.5 ∼ 1.7 : 0.8 ∼ 2.1 :1 ∼ 2.2 의 중량비로 배합하는 것이 바람직하며, 보다 바람직하게는 5 ~ 6 : 1 : 1.1 ~ 2.1 : 1.8 이다. In the mixed composition of the present invention, Cordyceps sinensis extract, buckwheat rice extract, phosphorus mugwort extract and cinnamon extract are preferably blended in a weight ratio of 4-8: 0.5-1.7: 0.8-2.1: 1-2.2, more preferably 5-6 1: 1.1 ~ 2.1: 1.8
본 발명은 상기의 실험으로 선정된 동충하초, 메밀쌀, 인진쑥 또는 계피를 주성분으로 포함하거나 이 소재들을 상기의 중량비로 배합하여 혈당강하 효과를 통해 당뇨병을 개선시키는 기능성식품을 제조한 것으로 이는 과립제, 음료, 생식, 경질캡슐제, 연질캡슐제, 환제 및 정제 등으로 제조될 수 있다.The present invention comprises a cordyceps, buckwheat rice, phosphorus mugwort or cinnamon selected in the above experiment as a main ingredient or by combining these materials in the above weight ratio to produce a functional food to improve diabetes through a hypoglycemic effect, which is a granule, beverage , Raw food, hard capsules, soft capsules, pills and tablets may be prepared.
본 발명의 과립형태, 캡슐형태 또는 정제형태의 사용량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으나, 1 내지 5g의 양을 일일 1회 내지 수회 경구투여할 수 있다. 또한 그 투여량은 질병의 정도, 성별, 체중, 나이 등에 따라서 증감될 수 있다. The amount of the granules, capsules or tablets of the present invention may vary depending on the age, sex and weight of the patient, but may be administered orally in an amount of 1 to 5 g once or several times daily. The dosage may also be increased or decreased depending on the severity of the disease, sex, weight, age and the like.
본 발명은 생약소재를 주성분으로 하는 식품이므로 독성 및 부작용이 없어서 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있는 것이다.The present invention is a food containing the herbal ingredients as a main ingredient there is no toxicity and side effects can be used with confidence even for long-term use for prophylactic purposes.
이하 본 발명을 자세히 설명하기로 한다.Hereinafter, the present invention will be described in detail.
본 발명의 당뇨병 환자를 위한 기능성 음료는 동충하초, 메밀쌀, 인진쑥 및 계피를 혼합한 중량에 대하여 20배의 정제수를 가한 다음, 100 ~ 150℃에서 2 ~ 4시간 열수 추출한 다음, 150~250메쉬 필터로 여과한 다음 70~100℃에서 가열하고 병에 충진한 다음 30℃ 이하로 냉각시켜 제조한다.Functional drink for diabetic patients of the present invention is added to 20 times purified water based on the mixed weight of Cordyceps sinensis, buckwheat rice, phosphorus mugwort and cinnamon, and then hot water extraction at 100 ~ 150 ℃ 2 ~ 4 hours, 150 ~ 250 mesh filter After filtration and heating at 70 ~ 100 ℃, filled in a bottle and cooled to below 30 ℃ to prepare.
본 발명의 기능성음료는 동충하초, 메밀쌀, 인진쑥 및 계피를 주성분으로 하므로 그 외에 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 식품학적으로 허용되는 첨가물, 부형제 또는 향미제 등을 추가 성분으로서 함유할 수 있다. 이때 식품학적으로 허용되는 첨가물, 부형제 또는 향미제로는 비타민 B1, 비타민 B2, 비타민 C, 비타민 B6, 니코틴산아미드, 구연산, 액상과당, 스테비오사이드, 말 토덱스트린, 마뉴카벌꿀, 사과농축액, 락추로오스분말, 실리코알루민산나트륨, 자당지방산에스테르, 히드록시프로필메칠셀룰로오스, 글리세린지방산에스테르, 산화아연, 베타-시클로덱스트린 등이 있다. 추가 성분은 주성분인 동충하초, 메밀쌀, 인진쑥 및 계피의 혼합액 100ml당 일반적으로 약 1 ~ 20g, 바람직하게는 약 5 ~ 12g이다.Since the functional beverage of the present invention contains Cordyceps sinensis, buckwheat rice, phosphorus mugwort, and cinnamon as main ingredients, there are no special limitations on the liquid components, and as a further ingredient, food additives, excipients or flavorings, such as ordinary beverages, may be included as additional ingredients. Can be. At this time, food additives, excipients or flavorings that can be used include vitamin B1, vitamin B2, vitamin C, vitamin B6, nicotinamide, citric acid, liquid fructose, stevioside, maltodextrin, manuka honey, apple concentrate, lacchurose Powder, sodium silicate, sucrose fatty acid ester, hydroxypropyl methyl cellulose, glycerin fatty acid ester, zinc oxide, beta-cyclodextrin and the like. The additional component is generally about 1 to 20 g, preferably about 5 to 12 g, per 100 ml of a mixture of main cordyceps, buckwheat rice, phosphorus mugwort and cinnamon.
본 발명의 당뇨병 환자를 위한 기능성 과립제는 동충하초를 원적외선 건조기로 건조한 후 기류식 분쇄기로 150~250 메쉬필터로 100% 통과시켜 분말을 얻고 인진쑥은 정제수 90~100%의 비율로 하여 1.2kg/cm3으로 10~15시간 열수 추출한 후 그 농축액을 진공동결건조하고 이것을 건식 분쇄기로 분쇄한 후 80~120메쉬 필터에 100% 통과시켜 분말을 얻는다. 계피는 물로 세척한 뒤 건조하고 기류식 분쇄기에서 150~250 매쉬로 분쇄하여 분말을 얻고 메밀쌀은 메밀쌀 10%, 에틸 알콜 60~70%, 정제수 20~30%의 비율로 섞은 뒤 10~20℃에서 45~50시간 추출한 후 진공 동결건조한 것을 건식 분쇄기로 분쇄한 후 150~200 메쉬필터로 100% 통과하여 분말을 얻는다. 이렇게 얻은 동충하초 분말, 인진쑥 분말, 메밀쌀 분말 및 계피 분말을 충분히 혼합한뒤 유동층으로 조립하기 위하여 유동층 조립기를 사용하여 혼합하고 스프레이 및 건조를 수회 반복한 뒤 수분 함량을 5% ~ 8% 로 조절하여 건조시켜 제조한다. 또한, 이경우 혼합단계에서 인진쑥은 분말상태로 분쇄하기 전인 농축액을 혼합하여 제조하여도 좋다.Functional granules for diabetic patients of the present invention after drying the Cordyceps sinensis with a far-
본 발명의 기능성 과립제는 제조시 유동층 조립기를 사용하여 혼합하고 스프레이 및 건조를 통하여 유동층으로 조립되었으므로 섭취하였을 경우 입안에서 즉석 용해가 가능하게 된다.Functional granules of the present invention are mixed using a fluidized bed granulator during manufacture and assembled into a fluidized bed through spraying and drying, so that instant dissolution is possible in the mouth when ingested.
본 발명의 기능성과립제는 동충하초 분말, 인진쑥 분말, 메밀쌀 분말 및 계피 분말의 혼합시에 혼합물 90~100g 당 보조인자인 TTP의 공급을 위해 티아민 플로라이드 0.01g를 첨가하고 Mg2 +의 공급을 위하여 스테아린산 마그네슘 5g을 첨가하고 Cr3+의 공급을 위하여 호모분말 0.05g을 함께 섞이도록 혼합하여 제조할 수 있다.Functional granules of the present invention is added to the fungus powder, injinssuk powder, rice flour, buckwheat and thiamine fluoride 0.01g for the supply of auxiliary factor design TTP mixture per 90 ~ 100g at the time of mixing of cinnamon powder, and stearic acid for the supply of the Mg 2 + It can be prepared by adding 5 g of magnesium and mixing to mix 0.05 g of homo-powder together for supply of Cr 3+ .
본 발명의 기능성음료 및 과립제에서 동충하초, 메밀쌀, 인진쑥 및 계피의 바람직한 중량비는 4 ∼ 8 : 0.5 ∼ 1.7 : 0.8 ∼ 2.1 :1 ∼ 2.2 이며, 보다 바람직하게는 5 ~ 6 : 1 : 1.1 ~ 2.1 : 1.8 이다. In the functional beverage and granules of the present invention, the weight ratio of Cordyceps sinensis, buckwheat rice, phosphorus mugwort and cinnamon is 4-8: 0.5-1.7: 0.8-2.1: 1-2.2, more preferably 5-6: 1: 1: 1.1-2.1 : 1.8.
상기와 같이 제조된 건강기능성 과립제를 성인 당뇨병 환자 남녀 각 10명을 공개모집하여 위약을 섭취하는 대조군과 비교함으로써 혈당강하 효과를 입증하였다. 위약은 상기 건조분말의 성분이 전혀 함유되지 않았으나 색상과 모양이 동일한 위약을 제작하였다. The hypoglycemic effect was demonstrated by comparing the health functional granules prepared as described above to 10 male and female adult diabetic patients and a control group taking placebo. Placebo did not contain any components of the dry powder, but a placebo having the same color and shape was prepared.
실험 내용 및 결과는 다음과 같다.The experiment contents and results are as follows.
공복 혈당 130mg/㎗이 식후 혈당 180mg/㎗ 이상인 성인(40~60세) 당뇨병 환자 남녀 각 10명을 공개 모집하여 실시예 15의 과립제를 1일 식후 3회 3g씩 섭취시킨 후 공복(식전) 혈당 및 식후 혈당 변화를 측정하였다. 실험 기간 중 매일 적당한 운동과 일정한 식사량을 유지하도록 하고, 음주 및 과식 등 평상적이지 못한 상황을 삼가도록 권고하나 부득이한 경우는 특이 사항으로 필히 기록하도록 하여 결과 산출시 고려하였다. Fasting blood glucose 130 mg / 후 post-prandial blood sugar 180 mg / ㎗ or more adults (40-60 years old) diabetic recruitment of 10 men and women each, taking the granules of Example 15 3g three times a day after fasting (fasting) And postprandial blood sugar change was measured. During the test period, it is recommended to maintain proper exercise and regular diet every day, and to avoid unusual situations such as drinking and overeating.
예비단계로서 실험 전 3일 정도의 예비 기간 동안 식전 혈당과 식후 30분에서 180분까지 30분 간격으로 혈당을 측정하게 하여 각 개인의 식전혈당, 식후 최대 혈당 및 도달 시간을 알아내어 섭취 전 수치로 사용하였다. 평균값을 데이터로 사용하며, 개인마다 식후 최대치의 혈당을 나타내는 시간을 확인하여 식후 혈당 측정 시간을 정하였다. 예비단계가 종료된 후 실험 대상자를 기능성식품군 및 위약군으로 절반씩 나누어 5주간 복용시킨 후 매일 공복 혈당 및 식후 혈당 변화 측정하게 하였다. As a preliminary step, pre-preparation blood sugar and blood glucose were measured at 30-minute intervals from 30 minutes to 180 minutes after meals for 3 days before the experiment. Used. The mean value was used as the data, and the time taken to measure the blood glucose level was determined by confirming the time indicating the maximum blood sugar level after each meal. After the preliminary stage was completed, the test subjects were divided into the functional food group and the placebo group for 5 weeks, and then the fasting blood sugar and the postprandial blood glucose change were measured daily.
[표4] 기능성식품군의 섭취 후 혈당측정 결과(단위 mg/㎗)[Table 4] Blood glucose measurement result after intake of functional food group (unit mg / ㎗)
[표5] 위약군의 섭취 후 혈당측정 결과(단위 mg/㎗)Table 5 Results of Blood Glucose Measurement after Intake of Placebo Group (Unit mg / dL)
[표6] 기능성식품군의 섭취 전과 섭취 후 5주차째 혈당변화Table 6 Changes in blood sugar levels before and after intake of functional food group
상기 표에서 혈당 측정 결과를 보면, 위약군에서는 혈당 변화가 거의 없는 반면에, 기능성식품군에서는 남자의 경우 식전 혈당이 36% 감소하였으며, 식후 혈당은 40%감소하였고 여자의 경우는 식전 혈당이 29% 감소하였으며 식후 혈당이 38% 감소하였다. 그리하여, 결국 남녀 전체 평균은 식전 혈당이 173에서 120으로 약 36%, 그리고 식후 혈당이 275에서 165로 약 37% 감소하였음을 알 수 있었다.In the table, the blood glucose change was almost unchanged in the placebo group, whereas in the functional food group, pre-prandial blood sugar decreased by 36%, post-prandial blood sugar decreased by 40% in men and 29% in pre-meal glucose in women. Postprandial blood sugar decreased by 38%. Thus, the average of all males and females showed that pre-prandial blood sugar decreased by 36% from 173 to 120 and post-prandial blood sugar decreased by 37% from 275 to 165.
상기 실험의 기능성식품군은 생약혼합조성물이 함유된 식품으로 혈당강하제나 인슐린과 같은 약제를 통하지 않고도 단 5주동안 약 40%의 혈당강하효과가 나타남을 확인할 수 있었다.The functional food group of the experiment was a food containing a herbal mixture composition, it was confirmed that the blood glucose lowering effect of about 40% for only 5 weeks without the use of drugs such as hypoglycemic agents or insulin.
이하 본 발명을 실시예에 의하여 상세히 설명한다. 단, 실시예는 본 발명을 예시하기 위한 것이지 이들만으로 한정하는 것은 아니다.Hereinafter, the present invention will be described in detail by examples. However, an Example is for illustrating this invention and is not limited only to these.
실험예Experimental Example 1. 동충하초( Cordyceps sinensis ( CordycepsCordyceps militarismilitaris )로부터 유효 성분의 추출Extraction of Active Ingredients from
동충하초 중에서 Cordyceps militaris 종의 건조 분말 24g을 80℃의 200ml 더운 물로 100시간 동안 열수 추출하였고 원심분리하여 상청액(분획물 A)을 얻었다. 열수 추출 후 남은 잔여물에 28g의 5% Na2CO3로 상온에서 24시간 동안 추출하고, 원심분리한 뒤 다시 그 잔여물에 NaBH4를 포함한 5% NaOH로 상온에서 24시간 추출하여 추출물을 원심분리하여 상청액(분획물 B)를 얻었다. 동충하초(Cordyceps militaris)에 함유된 분획물 A 와 분획물 B의 비율은 1:2로 존재한다.24 g of dry powder of Cordyceps militaris species in Cordyceps sinensis was hydrothermally extracted with 200 ml hot water at 80 ° C. for 100 hours and centrifuged to obtain a supernatant (fraction A). The remaining residue after hot water extraction was extracted with 28 g of 5% Na 2 CO 3 at room temperature for 24 hours, centrifuged and then the residue was extracted with 5% NaOH containing NaBH 4 at room temperature for 24 hours to centrifuge the extract. Isolate to obtain supernatant (fraction B). Fraction A and Fraction B contained in Cordyceps militaris have a ratio of 1: 2.
실험예Experimental Example 2. 2. 메밀쌀Buckwheat Rice , , 메밀피Buckwheat 또는 메밀싹으로부터의 유효 성분의 추출 Or extraction of active ingredients from buckwheat sprout
메밀쌀, 메밀피 또는 메밀싹 각각을 5배의 상온의 증류수로 씻은 다음, 40℃의 드라이 오븐에서 완전히 건조시키고, 840∼500㎛의 분말상태로 간 다음, 분말 상태의 24g을 40℃의 50% 에탄올 256ml을 용매로 하여 12시간동안 150rpm으로 인큐베이터에서 잘 흔들고 원심 분리하여 추출하였다.Buckwheat rice, buckwheat buckwheat or buckwheat sprouts were each washed with 5 times distilled water at room temperature, and then completely dried in a dry oven at 40 ° C., and then powdered at 840 to 500 μm. 256 ml of% ethanol as a solvent was extracted well by shaking in a incubator at 150 rpm for 12 hours and centrifuged.
실험예Experimental Example 3. 3. 인진쑥Injin mugwort , 계피, 민들레, , Cinnamon, dandelion, 차가버섯Chaga Mushroom , 당귀, , Donkey, 피부백삼Skin white ginseng , , 오가목Ogamok , , 황기Astragalus 또는 or 녹색입홍합으로부터From green lipped mussel 유효 성분의 추출 Extraction of Active Ingredients
인진쑥, 계피 , 민들레, 차가버섯, 당귀, 피부백삼, 오가목, 황기 또는 녹색입홍합 각각을 5배의 상온의 증류수로 씻은 다음, 40℃의 드라이 오븐에서 완전히 건조시키고, 840∼500㎛의 분말상태로 간 다음, 분말 상태의 24g을 40℃의 증류수 256ml을 용매로 하여 12시간동안 150rpm으로 인큐베이터에서 잘 흔들고 원심 분리하여 추출하였다.Each of Injin mugwort, cinnamon, dandelion, chaga, Angelica, skin ginseng, oleander, Astragalus or green lipped mussel is washed with 5 times distilled water at room temperature, and then completely dried in a dry oven at 40 ° C. Then, 24 g of powdered state was extracted by shaking well in a incubator at 150 rpm for 12 hours using 256 ml of distilled water at 40 ° C. as a solvent and centrifuging.
실험예Experimental Example 4. 4. 메밀피와Buckwheat and 메밀싹의 비율을 1:3, 2:2 또는 3:1로 하여 혼합한 것으로부터의 유효 성분의 추출 Extraction of Active Ingredients from Mixtures of Buckwheat Sprouts in a Ratio of 1: 3, 2: 2 or 3: 1
메밀피와 메밀싹을 1:3, 2:2, 3:1 의 비율로 혼합한 것의 각각을 5배의 상온의 증류수로 씻은 다음, 40℃의 드라이 오븐에서 완전히 건조시키고, 840∼500㎛의 분말상태로 간 다음, 분말 상태의 24g을 40℃의 50% 에탄올 256ml을 용매로 하여 12시간동안 150rpm으로 인큐베이터에서 잘 흔들고 원심 분리하여 추출하였다.Each of the mixture of buckwheat and buckwheat sprouts in a ratio of 1: 3, 2: 2, and 3: 1 was washed with 5 times distilled water at room temperature, and then completely dried in a dry oven at 40 ° C. After going to a powder state, 24 g of the powder state was extracted by shaking well in a incubator at 150 rpm for 12 hours using 256 ml of 50% ethanol at 40 ° C. for 12 hours.
실험예Experimental Example 5. 5. 글루코키나아제Glucokinase 활성 측정 Active measurement
[도 4]에 도시된 것처럼, 글루코스가 6-포스포글루네이트로 분해되는 과정에 서 NADPH가 생성되므로 NADPH의 생성량은 글루코키나아제의 활성에 비례할 것이다. 그러므로, 샘플과 반응 완충제(44mM Gly-Gly, 7.5mM MgCl2, 3mM ATP, 0.4U G6P-DH, 0.75mM NADP+), 그리고 100mM 글루코스를 시험관에 넣고 28℃에서 15분간 반응시키고 간의 싸이토졸(cytosol)을 첨가한 후 즉시 cuvette에 옮겨 340nm의 스펙트로포토메타에서 초기 흡광도를 측정하고 생성된 NADPH의 양을 1분 간격으로 3분 동안 측정하였다. 또한 0.5mM 글루코스로 헥소키나아제(hexokinase)에 의한 NADPH 생성량에 대한 보정을 하였고, NADPH의 몰흡광 계수인 ε340nm = 6.22cm2/μmol 를 이용하여 생성된 양을 계산하였다. 글루코키나아제의 활성도는 분당 NADPH의 생성량을 대조군에 대한 백분율로서 표시하였으며, 모든 실험은 2회 3반복 실시하여 그 평균값을 사용하였다. As shown in FIG. 4, since NADPH is produced during the decomposition of glucose into 6-phosphoglunate, the amount of NADPH produced will be proportional to the activity of glucokinase. Therefore, the sample and reaction buffer (44 mM Gly-Gly, 7.5 mM MgCl 2 , 3mM ATP, 0.4U G6P-DH, 0.75mM NADP + ), and 100mM glucose were added to the test tube and reacted at 28 ° C for 15 minutes, and after adding the cytosol of the liver, immediately transferred to the cuvette, and then initially at 340 nm spectrophotometer. Absorbance was measured and the amount of NADPH produced was measured at 1 minute intervals for 3 minutes. In addition, the amount of NADPH produced by hexokinase was corrected with 0.5 mM glucose, and the amount produced using the molar extinction coefficient ε 340 nm = 6.22 cm 2 / μmol of NADPH was calculated. The activity of glucokinase was expressed as the percentage of NADPH produced per minute as a percentage of the control group, and all experiments were repeated three times twice and the average value was used.
글루코키나아제의 보조인자로서 Cr3 +, Mg2 + 및 TPP 을 첨가하였으며, 다양한 시도를 통해 최종적으로는 TPP는 1mM, Mg2 +은 7.5mM, Cr3 +는 1mM이 최적임을 확인하였다. 또한 보조인자의 효능 비교를 위해 세가지 보조인자를 다 첨가한 경우와 Cr3+을 제외하였을때, 그리고 세가지 보조인자를 다 첨가하지 않은 경우를 비교 확인하였다. Was added to the Cr 3 +, Mg 2 + and TPP as a cofactor of glucokinase, finally the TPP over a wide range of attempts to 1mM, 7.5mM Mg 2 + is, Cr + 3 is It was confirmed that 1 mM was optimal. Also, to compare the efficacy of the cofactors, we compared the case of adding all three cofactors, excluding Cr 3+ , and not adding all three cofactors.
실험예Experimental Example 6. 6. 피루베이트Pyruvate 디하이드로게나아제Dehydrogenase 활성 activation
[도 5]에서 피루베이트 디하이드로게나아제에 의해서 피루베이트가 아세틸-코에이로 분해되며 이 아세틸-코에이가 ρ-니트로아닐린과 반응하여 아세틸-니트로아닐린으로 분해되므로 ρ-니트로아닐린의 반응량은 피루베이트 디하이드로게나아제의 활성에 비례할 것이다. 그러므로 샘플과 반응 완충액(25mM KH2PO4, 1mM ρ-니트로아닐린, 1mM MgCl2, 2mM 2-멀캅토에탄올, 10mU 아릴아민 아세틸트랜드퍼라아제, 1mM TPP, 0.5mM NAD+, 0.1mM CoA, 2.5㎍/㎖ 락테이트 디하이드로게나아제), 그리고 20mM 피루베이트를 시험관에 넣고 25℃에서 5분간 반응시키고 심장의 미토콘드리아를 첨가한 후 즉시 큐베트에 옮겨 410nm의 스펙트로포토메타에서 초기 흡광도를 측정하고 반응한 ρ-니트로아닐린의 양을 1분 간격으로 3분 동안 측정하였고, ρ-니트로아닐린의 물흡광 계수인 ε410nm = 8.8cm2/μmol를 이용하여 반응한 양을 계산하였다. 피루베이트 디하이드로게나아제의 활성도는 분당 ρ-니트로아닐린의 반응량을 대조군에 대한 백분율로서 표시하였으며, 모든 실험은 2회 3반복 실시하여 그 평균값을 사용하였다. 피루베이트 디하이드로게나아제의 보조인자로서 Cr3 +, Mg2 + 및 TPP 을 첨가하였으며, 다양한 시도를 통해 최종적으로는 TPP는 1mM, Mg2+은 7.5mM, Cr3 +는 1mM이 최적임을 확인하였다. 또한 보조인자의 효능 비교를 위해 세가지 보조인자를 다 첨가한 경우와 Cr3+을 제외하였을때, 그리고 세가지 보조인자를 다 첨가하지 않은 경우를 비교 확인하였다. In FIG. 5, pyruvate is decomposed into acetyl-coei by pyruvate dehydrogenase, and the acetyl-coei is decomposed into acetyl-nitroaniline by reaction with ρ-nitroaniline, thereby reacting with ρ-nitroaniline. Will be proportional to the activity of pyruvate dehydrogenase. Thus, the sample and reaction buffer (25 mM KH 2 PO 4 , 1 mM ρ-nitroaniline, 1 mM MgCl 2, 2 mM 2-mercaptoethanol , 10 mM arylamine acetyltransferase, 1 mM TPP, 0.5 mM NAD +, 0.1 mM CoA, 2.5 μg / Ml lactate dehydrogenase) and 20 mM pyruvate were added to the test tube and reacted at 25 ° C. for 5 minutes. After adding mitochondria of the heart, they were immediately transferred to cuvettes, and the initial absorbance was measured and reacted at 410 nm spectrophotometer. The amount of ρ-nitroaniline was measured for 3 minutes at 1 minute intervals and the amount of reaction was calculated using ε- 410 nm = 8.8 cm 2 / μmol, the water absorption coefficient of ρ-nitroaniline. The activity of pyruvate dehydrogenase was expressed as the percentage of ρ-nitroaniline per minute as a percentage of the control group, and all experiments were repeated three times and used as the average value. Pyruvate-dihydro-3 + Cr as a co-factor of the dehydrogenase kinase, was added a Mg 2 + and TPP, and finally TPP over a wide range of attempts to 1mM, 7.5mM Mg 2+ is, Cr + 3 is It was confirmed that 1 mM was optimal. Also, to compare the efficacy of the cofactors, we compared the case of adding all three cofactors, excluding Cr 3+ , and not adding all three cofactors.
실험예Experimental Example 7. 아세틸- 7. Acetyl 코에이Koei 카르복시라제Carboxylase 활성 activation
[도 6]에 따라 NADH의 반응량을 측정하여 아세틸-코에이의 활성치를 측정한 바, 심플과 반응 완충제(50mM Tris·HCl, 10mM 구연산칼륨, 3.75mM 글루타티온 0.0125mM NADH, 0.2mg BSA, 0.125mM 아세틸-코에이, 10mM MgCl2, 0.5mM 칼륨 포스포에노피무베이트 0.009mg 피루베이트 키나아제, 0.002mg 락테이트 디하이드로게나아제), 그리고 간의 사이토졸을 시험관에 넣고 37℃에서 12분간 반응시키고, 3.75mM ATP 첨가한 후 다시 37℃에서 1분간 더 반응시킨 후에 25mM KHCO3을 첨가하고 즉시 큐베트에 옮겨 340nm의 스펙트로포토메타에서 초기 흡광도를 측정하고 반응한 NADH의 양을 1분 간격으로 3분 동안 측정하였고, NADH의 물흡광 계수인 ε340nm = 6.22cm2/μmol를 이용하여 반응한 양을 계산하였다. 아세틸-코에이 카르복시라제의 활성도는 분당 NADH의 반응량을 대조군에 대한 백분율로서 표시하였으며, 모든 실험은 2회 3반복 실시하여 그 평균값을 사용하였다. 아세틸-코에이 카르복시라제의 Cofactor로서 Cr3+, Mg2+을 첨가하였으며, 다양한 시도를 통해 최종적으로는 Mg2+은 7.5mM, Cr3+는 1mM이 최적임을 확인하였다. 또한 보조인자의 효능 비교를 위해 세가지 보조인자를 다 첨가한의 경우와 Cr3+을 제외하였을때, 그리고 세가지 보조인자를 다 첨가하지 않은 경우를 비교 확인하였다. According to FIG. 6, the reaction amount of NADH was measured and the activity value of acetyl-Coei was measured. Simple and reaction buffers (50 mM Tris-HCl, 10 mM potassium citrate, 3.75 mM glutathione) 0.0125mM NADH, 0.2mg BSA, 0.125mM Acetyl-Coei, 10mM MgCl 2 , 0.5mM Potassium Phosphoenopymubate 0.009mg Pyruvate Kinase, 0.002mg Lactate Dehydrogenase), and Liver Cytosol After reacting at 37 ° C. for 12 minutes, adding 3.75 mM ATP, and then further reacting at 37 ° C. for 1 minute, 25 mM KHCO 3 was added and immediately transferred to cuvettes, and the initial absorbance was measured and reacted at 340 nm spectrophotometer. The amount of NADH was measured for 3 minutes at 1 minute intervals, and the amount of reaction was calculated using ε 340 nm = 6.22 cm 2 / μmol, the water absorption coefficient of NADH. The activity of acetyl-Coei carboxylase expressed the reaction amount of NADH per minute as a percentage with respect to the control group, and all experiments were repeated three times twice and the average value was used. Cr 3+ and Mg 2+ were added as cofactors of acetyl-Coay carboxylase. Finally, Mg 2+ was 7.5 mM and Cr 3+ was It was confirmed that 1 mM was optimal. Also, to compare the efficacy of the cofactors, we compared the case of adding all three cofactors, excluding Cr 3+ and the case of not adding all three cofactors.
[실시예 14] 기능성음료 제조 Example 14 Functional Beverage Preparation
동충하초 50g, 메밀쌀 20g, 인진쑥 10g 및 계피15g을 혼합한 중량에 대하여 20의 정제수를 가한 다음, 120℃에서 3시간 열수 추출한 다음, 200메쉬 필터로 여과하고 여과액에 비타민 C와 감초농축액을 혼합한 다음 90℃에서 10분간 가열하고 180ml 병에 충진한 다음 30℃ 이하로 냉각시킨다.To 20 g of Cordyceps sinensis, 20 g of buckwheat rice, 10 g of phosphorus mugwort and 15 g of cinnamon were added, purified water of 20 was added, extracted with hot water at 120 ° C. for 3 hours, filtered through a 200 mesh filter and mixed with vitamin C and licorice concentrate in the filtrate. Then, heated at 90 ° C. for 10 minutes, filled into 180 ml bottles, and cooled to 30 ° C. or lower.
[실시예 15] 기능성 과립제 제조Example 15 Preparation of Functional Granules
동충하초를 원적외선 건조기로 건조한 후 기류식 분쇄기로 200메쉬필터로 100% 통과시켜 분말을 얻고 정제수 96%의 비율의 인진쑥을 1.2kg/cm3 으로 12시간 열수 추출한 후 그 농축액을 동결건조하고 이것을 건식 분쇄기로 분쇄한 후 100메쉬 필터에 100% 통과시켜 분말을 얻는다. 계피는 물로 세척한 뒤 원적외선 건조기로 건조하고 기류식 분쇄기에서 200매쉬로 분쇄하여 분말을 얻고 메밀쌀은 메밀쌀 10%, 에틸 알콜 63%, 정제수 27%의 비율로 섞은 뒤 15℃에서 48시간 추출한 후 진공 동결건조한 것을 건식 분쇄기로 분쇄한 후 100메쉬 필터로 100% 통과하여 분말을 얻는다. 이렇게 얻은 동충하초 분말 50g, 인진쑥 분말 10g, 메밀쌀 분말 15g 및 계피 분말 15g과 티아민 플로라이드 0.01g, 스테아린산 마그네슘 5g, 효모분말 0.05g을 충분히 섞이도록 혼합한다. 유동층으로 조립하기 위하여 당귀 4%에 정제수 96%의 비율로 열수추출하여 100메쉬 필터에 통과한 고착제액과 에틸 알콜을 혼합하 여 유동층 조립기를 사용하여 30분 혼합하고 스프레이 및 건조를 5회 반복한 뒤 수분 함량을 5%로 조절하여 건조시킨 후 3g 단위로 포장한다. 또한, 이 경우 혼합단계에서 인진쑥은 분말상태로 분쇄하기 전인 농축액 10g을 혼합하여 제조한다. After drying the Cordyceps sinensis with a far-infrared dryer, passing 100% with a 200 mesh filter using an air flow type grinder to obtain powder, and extracting hot water of 96% of purified water at 1.2kg / cm 3 for 12 hours, lyophilizing the concentrated liquid and drying it. After pulverizing with 100% through a 100 mesh filter to obtain a powder. Cinnamon was washed with water, dried in a far-infrared dryer and pulverized with 200 mesh in an airflow crusher to obtain powder. Buckwheat rice was mixed at a rate of 10% buckwheat rice, 63% ethyl alcohol, and 27% purified water, and extracted at 15 ° C. for 48 hours. After vacuum lyophilization was pulverized with a dry mill and then 100% through a 100 mesh filter to obtain a powder. 50 g of Cordyceps sinensis powder, 10 g phosphorus mugwort powder, 15 g buckwheat rice powder, 15 g cinnamon powder, 0.01 g thiamine fluoride, 5 g magnesium stearate, and 0.05 g yeast powder are mixed. In order to assemble into a fluidized bed, hot water was extracted at a ratio of 4% of Angelica sinensis and 96% of purified water, and the fixing agent solution and ethyl alcohol, which had passed through the 100 mesh filter, were mixed for 30 minutes using a fluidized bed granulator and sprayed and dried five times. After drying by adjusting the moisture content to 5% and packaging in 3g units. In this case, in the mixing step, the ginjinmyeong is prepared by mixing 10 g of the concentrate before grinding into a powder state.
[실시예 16] 기능성 생식식품 제조Example 16 Functional Raw Food Preparation
동충하초, 메밀쌀, 인진쑥, 계피, 호박, 케일, 신선초, 당근, 시금치, 부추, 양파, 마늘, 돌미나리 및 무우를 25℃의 수도수로 3회 세척하고 차아염소산소다 25ppm에 25초간 침적 후 건져내어 살균한뒤 다시 잔류염소제거를 목적으로 25℃ 수도수를 유슈형태로 하여 세척하여 1mm 단위로 자른다. 24시간동안 -30℃에서 예비동결시킨 뒤 -45℃ 트랩, 진공도 1×10-1 Torr로 40시간 진공 동결 및 건조시키고 건식 분쇄기로 80매쉬 필터에 100% 통과시켜 제조한다.Cordyceps sinensis, buckwheat rice, jinjin mugwort, cinnamon, pumpkin, kale, fresh vinegar, carrot, spinach, leek, onion, garlic, parsley and radish are washed three times with tap water at 25 ℃ and immersed in 25ppm of sodium hypochlorite for 25 seconds. After sterilization, wash 25 ℃ tap water in the form of yushu for the purpose of removing residual chlorine and cut into 1mm units. Pre-freeze at -30 ℃ for 24 hours, -45 ℃ trap, vacuum freeze and dry for 40 hours with a vacuum degree of 1 × 10 -1 Torr and prepared by passing 100% through an 80 mesh filter with a dry mill.
이상에서 설명한 바와 같이 본 발명은 포도당 대사 과정에 있어서 관련된 효소들을 활성시키는 작용이 있는 천연생약 추출물을 주성분으로 함유하는 당뇨병 환자를 위한 기능성 식품을 제공한다. As described above, the present invention provides a functional food for diabetic patients containing a natural herbal extract as an active ingredient, which has an action of activating related enzymes in the process of glucose metabolism.
이로써 본 발명은 기존의 인슐린이나 경구 혈당 강하제의 투여의 한계를 개선시기키에 유용한 기능성식품을 제공하여 약물치료에 따른 부작용 없이 당뇨병 증상을 개선시킴으로서 고혈당관리에 효율적으로 활용될 수 있다. 그리고, 생약 성 분을 추출한 식품이므로 대량생산의 가능성 및 다양한 활용을 기대할 수 있다.As a result, the present invention provides a functional food useful for improving the limitation of administration of the existing insulin or oral hypoglycemic agent, thereby improving diabetes symptoms without side effects due to drug treatment, and thus can be effectively used for hyperglycemia management. And, since it is a food extracted from herbal components, it can be expected the possibility of mass production and various applications.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050062513A KR100714076B1 (en) | 2005-07-12 | 2005-07-12 | A functional food containing composition for the improvement of diabetes mellitus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050062513A KR100714076B1 (en) | 2005-07-12 | 2005-07-12 | A functional food containing composition for the improvement of diabetes mellitus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20070008763A true KR20070008763A (en) | 2007-01-18 |
| KR100714076B1 KR100714076B1 (en) | 2007-05-02 |
Family
ID=38010686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020050062513A KR100714076B1 (en) | 2005-07-12 | 2005-07-12 | A functional food containing composition for the improvement of diabetes mellitus |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100714076B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112617191A (en) * | 2020-12-18 | 2021-04-09 | 高思华 | Medicinal and edible composition for improving glycometabolism and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19980020507A (en) * | 1996-09-09 | 1998-06-25 | 김진봉 | Method of manufacturing buckwheat processed foods reinforced with rutin |
| JP3509781B2 (en) * | 2001-06-25 | 2004-03-22 | 株式会社半導体理工学研究センター | Method for manufacturing semiconductor device |
| KR100503230B1 (en) * | 2002-05-23 | 2005-07-25 | 주식회사 내츄로바이오텍 | Composition for improving hyperglycemia and inhibiting development of diabetes induced complication containing plant extracts |
| KR101035710B1 (en) * | 2003-03-07 | 2011-05-19 | 문창규 | Artemisia capillaries Thunb extracts and diabetes therapeutics using thereof |
| KR20050040901A (en) * | 2005-04-13 | 2005-05-03 | 이승정 | Health care food containing a polysaccharide fraction isolated from cordyceps militaris for preventing and improving diabetes mellitus |
-
2005
- 2005-07-12 KR KR1020050062513A patent/KR100714076B1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112617191A (en) * | 2020-12-18 | 2021-04-09 | 高思华 | Medicinal and edible composition for improving glycometabolism and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100714076B1 (en) | 2007-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100750988B1 (en) | Composition having ginsenosides for treating or preventing diabetes | |
| CN101264177B (en) | Tablet forming candy with refreshing, pharynx-clearing and throat-smoothing action | |
| Kochhar et al. | Effect of supplementation of traditional medicinal plants on blood glucose in non–insulin-dependent diabetics: A pilot study | |
| JP2015164955A (en) | Composition for increasing bioavailability of saponin | |
| KR100976241B1 (en) | Extract of sedum sarmentosum for alcohol oxidation and relieves hangover | |
| KR100675311B1 (en) | Method processing a functional food for the descent of blood sugar | |
| KR100952188B1 (en) | Health Food For The Descent Of HbA1c | |
| KR101226824B1 (en) | A composition comprising the extract of Sorghum bicolor L. Moench as an active ingredient for preventing and treating inflammatory disease | |
| KR100714076B1 (en) | A functional food containing composition for the improvement of diabetes mellitus | |
| KR20110006921A (en) | Composition for prevention and treatment of type 2 diabetes containing extract of gastrodia elata blume as an active ingredient | |
| KR101034986B1 (en) | Composition comprising the mixed herbal extract for relieving hangover | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| KR102368446B1 (en) | Composition for preventing or treating diabetes | |
| JP2000342228A (en) | Formulated tea of smallanthus sonchifol with mulberry leaf | |
| KR100505780B1 (en) | Healthy food composition having efficacy of anti-diabetic and its process | |
| KR100846521B1 (en) | Composition comprising an extract of herbal combination(oca-i) or the powder(oca-ii) thereof for preventing and treating diabetes mellitus | |
| KR101449670B1 (en) | Composition for preventing or treating diabetes or complications of diabetes mellitus comprising Rhododendron mucronulatum for. albiflorum extract | |
| KR100543405B1 (en) | Composition comprising the extract of Allium victorialis L. var. platyphyllum for treating or preventing diabetes mellitus | |
| KR20050100890A (en) | Composition comprising the extract of acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
| KR20110073801A (en) | Composition comprising the extract of mixed crude drug showing anti-allergic effect | |
| KR102161893B1 (en) | The food composition for anti-obesity comprising pine nut cones by-products | |
| KR20100042139A (en) | The composition comprising enzyme-treated extracts of momordica charantia l. for the prevention and treatment of diabetic complications | |
| KR100473529B1 (en) | Composition comprising an extract of sungisan crude drug complex as an effective ingredient for preventing and treating diabetes | |
| KR100731553B1 (en) | composition for the descent of blood sugar | |
| KR100478150B1 (en) | Health care food comprising an extract of the crude drug complex as an effective ingredient for preventing diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20101026 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |